New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Akebia Therapeutics, Inc.
AKBA
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

651M

Biotechnology

Next Earning date - 14 Aug 2025

651M

Biotechnology

Next Earning date - 14 Aug 2025

2.48USD

Shape0.05 ( 2.06%)
sun-fogPre-market 2.49$arrow-right-up0.01 (0.40%)
Market Closed (as of May 13, 20:00 EDT)
favorite-chart

Relative Strenght

87
favorite-chart

Volume Buzz

-30%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

14%

Quote Panel

Shape
Updated May 14, 2025
1W -5.34 % 1M 31.22 % 3M 19.81 % 1Y 110.17 %

Key Metrics

Shape
  • Market Cap

    651.34M


  • Shares Outstanding

    262.64M


  • Share in Float

    251.86M


  • Dividende

    0


  • Earning Date

    14 Aug 2025


  • Price Target

    2.48


  • Average Volume

    4.50M


  • Beta

    0.876


  • Range

    0.8-2.9


  • Industry

    Biotechnology


  • Website

    https://www.akebia.com


  • Sector

    Healthcare


Fundamentals

Shape

Relative Strength

Shape

AKBA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$276M

Shape382%

2026-Revenue

$0.00

Shape-107%

2026-EPS

$125M

Shape-1028%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

0.00(-100.00%)

Number of analyst

0

Last analyst upgrade/downgrade

Seaport Global

downgrade

Previous: Not converted

2023-05-31

Now: Sector Weight

Piper Sandler

upgrade

Previous: Not converted

2023-05-31

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

N/A

-0.06
vs 0.23

Q3.23

arrow
arrow

N/A

-0.08
vs -0.28

Q4.23

arrow
arrow

+108%

0
vs -0.04

Q1.24

arrow
arrow

N/A

-0.09
vs -0.14

Q2.24

arrow
arrow

N/A

-0.04
vs -0.06

Q3.24

arrow
arrow

N/A

-0.10
vs -0.08

Q4.24

arrow
arrow

N/A

-0.10
vs 0

Q1.25

arrow
arrow

+133%

0.03
vs -0.09

Q2.25

arrow
arrow

N/A

-0.02
vs -0.04

Q3.25

arrow
arrow

N/A

-0.04
vs -0.10

Sales GrowthShape

status-upYoY

Current

Estimates

Q2.23

arrow
arrow

-56%

56.4M  vs 126.8M

Q3.23

arrow
arrow

-14%

42M  vs 49M

Q4.23

arrow
arrow

+2%

56.2M  vs 55.2M

Q1.24

arrow
arrow

-19%

32.6M  vs 40.1M

Q2.24

arrow
arrow

-23%

43.6M  vs 56.4M

Q3.24

arrow
arrow

-11%

37.4M  vs 42M

Q4.24

arrow
arrow

-17%

46.5M  vs 56.2M

Q1.25

arrow
arrow

+76%

57.3M  vs 32.6M

Q2.25

arrow
arrow

+6%

46.3M  vs 43.6M

Q3.25

arrow
arrow

+25%

46.7M  vs 37.4M

Return on EquityShape

status-upQoQ

Q2.23

arrow
arrow

+42%

0.42
vs 1.17

Q3.23

arrow
arrow

+37%

0.37
vs 0.42

Q4.23

arrow
arrow

-2%

-0.02
vs 0.37

Q1.24

arrow
arrow

+66%

0.66
vs -0.02

Q2.24

arrow
arrow

+25%

0.25
vs 0.66

Q3.24

arrow
arrow

+40%

0.4
vs 0.25

Q4.24

arrow
arrow

+46%

0.46
vs 0.4

Q1.25

arrow
arrow

+25%

0.25
vs 0.46

Institutionnal OwnershipShape

status-upQoQ

Q1.23

arrow
arrow

70

70
vs 79

-11%

Q2.23

arrow
arrow

83

83
vs 70

19%

Q3.23

arrow
arrow

80

80
vs 83

-4%

Q4.23

arrow
arrow

91

91
vs 80

14%

Q1.24

arrow
arrow

126

126
vs 91

38%

Q2.24

arrow
arrow

108

108
vs 126

-14%

Q3.24

arrow
arrow

119

119
vs 108

10%

Q4.24

arrow
arrow

126

126
vs 119

6%

Earnings Growth

Latest News